Anika Therapeutics/ANIK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Anika Therapeutics

Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.

Ticker

ANIK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Cheryl Blanchard

Employees

357

Headquarters

Bedford, United States
Website
anika.com

ANIK Metrics

BasicAdvanced
$380M
Market cap
-
P/E ratio
-$5.24
EPS
0.85
Beta
-
Dividend rate
$380M
0.84583
$28.67
$16.54
74K
5.585
3.849
-25.49%
-31.61%
-28.16%
2.247
1.823
1.932
7.49%
-244.27%
8.51%

What the Analysts think about ANIK

Analyst Ratings

Majority rating from 3 analysts.
Buy

ANIK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-11.11% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
-5.59%
Net income
-$4.5M
-92.86%
Profit margin
-11.11%
-92.43%

ANIK Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 66.07%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.45
-$4.30
-$0.31
-
Expected
-$0.27
-$0.37
-$0.26
-$0.19
$0.05
Surprise
-29.63%
20.54%
1,532.91%
66.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Anika Therapeutics stock?

Anika Therapeutics (ANIK) has a market cap of $380M as of June 15, 2024.

What is the P/E ratio for Anika Therapeutics stock?

The price to earnings (P/E) ratio for Anika Therapeutics (ANIK) stock is 0 as of June 15, 2024.

Does Anika Therapeutics stock pay dividends?

No, Anika Therapeutics (ANIK) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Anika Therapeutics dividend payment date?

Anika Therapeutics (ANIK) stock does not pay dividends to its shareholders.

What is the beta indicator for Anika Therapeutics?

Anika Therapeutics (ANIK) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Anika Therapeutics stock price target?

The target price for Anika Therapeutics (ANIK) stock is $31, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Anika Therapeutics stock

Buy or sell Anika Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing